This company listing is no longer active
AcuCort (NV5) Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NV5 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AcuCort AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.001 |
| 52 Week High | €0.07 |
| 52 Week Low | €0.001 |
| Beta | 1.52 |
| 1 Month Change | -97.39% |
| 3 Month Change | -97.28% |
| 1 Year Change | -98.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.44% |
Recent News & Updates
Shareholder Returns
| NV5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -9.6% | -5.4% |
| 1Y | -98.5% | 0.5% | -2.4% |
Return vs Industry: NV5 underperformed the German Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: NV5 underperformed the German Market which returned 7.3% over the past year.
Price Volatility
| NV5 volatility | |
|---|---|
| NV5 Average Weekly Movement | 31.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: NV5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NV5's weekly volatility has increased from 18% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 4 | Jonas Jonmark | www.acucort.com |
AcuCort AB (publ) operates as a pharmaceutical company. It offers Zeqmelit, an oral film containing the glucocorticoid dexamethasone for the treatment of acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and for the treatment of patients with COVID-19 who experience respiratory difficulties and require oxygen therapy. The company was incorporated in 2006 and is based in Lund, Sweden.
AcuCort AB (publ) Fundamentals Summary
| NV5 fundamental statistics | |
|---|---|
| Market cap | €201.86m |
| Earnings (TTM) | -€2.55m |
| Revenue (TTM) | €816.07k |
Is NV5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NV5 income statement (TTM) | |
|---|---|
| Revenue | SEK 8.63m |
| Cost of Revenue | SEK 20.65m |
| Gross Profit | -SEK 12.02m |
| Other Expenses | SEK 14.91m |
| Earnings | -SEK 26.93m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 20, 2026
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -139.38% |
| Net Profit Margin | -312.21% |
| Debt/Equity Ratio | 0% |
How did NV5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 12:10 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AcuCort AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.